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Abstract
Objectives To determine the respective efficacy of quetiapine
and rivastigmine for agitation in people with dementia in
institutional care and to evaluate these treatments with respect
to change in cognitive performance.
Design Randomised double blind (clinician, patient, outcomes
assessor) placebo controlled trial.
Setting Care facilities in the north east of England.
Participants 93 patients with Alzheimer’s disease, dementia,
and clinically significant agitation.
Intervention Atypical antipsychotic (quetiapine), cholinesterase
inhibitor (rivastigmine), or placebo (double dummy).
Main outcome measures Agitation (Cohen-Mansfield agitation
inventory) and cognition (severe impairment battery) at
baseline and at six weeks and 26 weeks. The primary outcome
was agitation inventory at six weeks.
Results 31 patients were randomised to each group, and 80
(86%) started treatment (25 rivastigmine, 26 quetiapine, 29
placebo), of whom 71 (89%) tolerated the maximum protocol
dose (22 rivastigmine, 23 quetiapine, 26 placebo). Compared
with placebo, neither group showed significant differences in
improvement on the agitation inventory either at six weeks or
26 weeks. Fifty six patients scored > 10 on the severe
impairment battery at baseline, 46 (82%) of whom were
included in the analysis at six week follow up (14 rivastigmine,
14 quetiapine, 18 placebo). For quetiapine the change in severe
impairment battery score from baseline was estimated as an
average of − 14.6 points (95% confidence interval − 25.3 to
− 4.0) lower (that is, worse) than in the placebo group at six
weeks (P = 0.009) and − 15.4 points ( − 27.0 to − 3.8) lower at 26
weeks (P = 0.01). The corresponding changes with rivastigmine
were − 3.5 points ( − 13.1 to 6.2) lower at six weeks (P = 0.5) and
− 7.5 points ( − 21.0 to 6.0) lower at 26 weeks (P = 0.3).
Conclusions Neither quetiapine nor rivastigmine are effective
in the treatment of agitation in people with dementia in
institutional care. Compared with placebo, quetiapine is
associated with significantly greater cognitive decline.
Introduction
People with dementia often experience intrusive neuropsychiat-
ric symptoms.1 These are distressing, present major difficulties
for caregivers, and accelerate nursing home placement. Antipsy-
chotic drugs are commonly prescribed to many people with
dementia (up to 45%) in residential or nursing homes,2 often for
prolonged periods. Antipsychotics have modest efficacy3 but are
commonly associated with substantial adverse effects such as
parkinsonism, tardive dyskinesia, reduced quality of life, and car-
diac arrhythmias. More seriously, an increased risk of stroke has
been reported in patients taking the two most widely prescribed
atypical antipsychotics, risperidone and olanzapine.4 Unfortu-
nately, there are no published randomised controlled trials for
other atypical antipsychotics in people with dementia, although
a published abstract indicates some benefit of quetiapine in
those with agitation.5 Preliminary evidence indicates that
cholinesterase inhibitors may improve agitation,6 though this has
not been supported by a randomised controlled trial.
One observational study reported a doubling in the rate of
cognitive decline in patients with dementia taking antipsychot-
ics.7 Although this was a landmark study, the patients were not
randomly allocated to treatment and participants were taking
typical antipsychotics. The impact on cognition of newer atypical
antipsychotics, which have better overall tolerability, was not
determined.
We compared quetiapine and rivastigmine with placebo in
patients with dementia and agitation in nursing homes in a ran-
domised double blind placebo controlled trial over 26 weeks.
Our primary objective was to determine whether either drug was
better than placebo for agitation. We also evaluated whether
there was a significant difference between the individual active
treatments and placebo with respect to cognitive change.
Method
Participants were all people with dementia living in care facilities
in Newcastle. Those with clinically significant agitation reported
by a member of staff or a physician were initially assessed for eli-
gibility using the Cohen-Mansfield agitation inventory.8 If the
total score exceeded 39 and the level of agitation was judged to
represent a clinically significant problem, we assessed the patient
for inclusion. Our inclusion criteria were a diagnosis of probable
or possible Alzheimer’s disease9; age > 60; clinically significant
agitation for at least six weeks and scores ≥ 4 on the irritability or
aberrant motor behaviour scales of the neuropsychiatric
inventory; and no use of antipsychotics or cholinesterase inhibi-
tors for four weeks before entry into the study. We excluded
patients known to be sensitive to cholinesterase inhibitors or
antipsychotics and those with advanced, severe, progressive, or
unstable disease that might interfere with efficacy or put the
patient at special risk; disability that might prevent them from
completing study procedures; those with severe, unstable, or
poorly controlled medical conditions; bradycardia ( < 50), sick
sinus syndrome, or conduction defects; current diagnosis of
active uncontrolled peptic ulceration within the past three
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months; and clinically significant urinary obstruction. All partici-
pants, or next of kin or other appropriate person if necessary,
gave informed consent.
Evaluations
We assessed all patients before the start of the pharmacological
intervention (baseline) and after six and 26 weeks. At 12 weeks
participants underwent an additional severe impairment
battery10 (to facilitate last observation carried forward) because
people with behavioural problems commonly refuse cognitive
assessment at least once. Assessors were blind to treatment allo-
cation.
Outcomes
Our primary outcome measure was a validated standardised
evaluation of agitation at six weeks.8 We used the severe impair-
ment battery for cognitive assessment. This scale was developed10
and used in pivotal trials to measure cognitive change in people
with severe dementia. General assessments included electrocar-
diography, full blood count, and evaluation of severity of demen-
tia (functional assessment staging)11 at baseline.
Randomisation
The study statistician randomly assigned patients in equal num-
bers to active quetiapine plus placebo rivastigmine; placebo
quetiapine plus active rivastigmine; or placebo rivastigmine plus
placebo quetiapine (double dummy). The allocations were com-
puter generated with block randomisation (block sizes of three
and six) with Stata software (release 7.0). The randomising clini-
cian faxed a form to the statistician, who communicated
allocation to the pharmacy, ensuring concealment.
We aimed to attain doses of 25-50 mg quetiapine twice a day
and 3-6 mg rivastigmine twice a day by week 12 and doses of 50
mg quetiapine twice a day or ≥ 9 mg rivastigmine daily between
week 12 and week 26. There is inadequate evidence for an opti-
mal dose of quetiapine for behavioural symptoms in dementia.
An open study indicated efficacy at 100 mg daily,12 which accords
with clinical experience and good practice principles of using
low doses in dementia.
Sample size and analysis
To detect an average difference of a 6 point (SD 6) change in agi-
tation inventory score from baseline to six weeks between active
treatment and placebo with a power of 90% at the 5% (two sided)
level of significance, we needed a sample size of 23 in each
group, assuming similar efficacy of active treatments. These
parameters are based on the effect reported for carbamazepine
in a similar study.13 With allowance for a drop out rate of 25%, we
therefore needed 31 patients per treatment group (n = 93).
We used SPSS (release 11.5.0) for Windows to manage data
and Stata (release 7.0) for analyses. Demographic factors and
clinical characteristics were summarised with counts (percent-
ages) for categorical variables, mean (SD) for normally
distributed continuous variables, or median (range) for other
continuous variables. We restricted comparative analysis to those
patients who had at least one assessment after randomisation. As
the trial was blinded, knowledge of allocation could not have
contributed to drop outs before or after treatment and so exclu-
sion of such patients did not impart bias. Thus we performed a
modified intention to treat analysis with all patients with
available data being analysed in the groups to which they were
allocated. For the agitation inventory score, for everyone who
completed the six week evaluation but dropped out thereafter we
carried forward the last total score. For the severe impairment
battery, we carried forward the last total score from either the six
week or supplementary three month assessment.
For the primary analysis, we summarised the change in the
agitation inventory score from baseline to six weeks using the
mean (SD). To establish the magnitude and direction of the
treatment effect, we used analysis of covariance to compare pairs
of treatment groups, giving the mean difference (in change in
agitation inventory from baseline to six weeks) between groups
(plus 95% confidence intervals) with adjustment for baseline
value. We also evaluated the change in the agitation inventory
score from baseline to 26 weeks and the changes in severe
impairment battery score. To allow us to detect a change we
excluded from the analysis those patients whose scores on the
severe impairment battery were < 10 because of the risk that
they would cluster unchanged at the lower end of the score range
(a “floor effect”).
We made no formal adjustment for multiple significance
testing. To meet our prespecified main objectives, our principal
comparisons were of active treatment versus placebo on the agi-
tation inventory and severe impairment battery at six weeks. We
have reported active treatment group comparisons primarily for
completeness given the dearth of published data. We also report
results at the 26 week follow up to show whether the effects are
temporary or sustained.
Results
Ninety three patients (31 per arm), most with severe dementia
(functional assessment staging scores > 5) were randomised
between September 2001 and April 2003, of whom 80 (86%)
started treatment (25 rivastigmine, 26 quetiapine, 29 placebo).
The 13 other participants either withdrew consent (10) or died
(3) before pharmacological treatment (fig 1). Seventy one (89%)
tolerated the maximum protocol dose (22 rivastigmine, 23
quetiapine, 26 placebo). Eighty seven (94%) completed the agita-
tion inventory assessment at baseline and 80 (86%) did so at six
weeks (24 rivastigmine, 27 quetiapine, 29 placebo). Wherever
possible we assessed outcomes irrespective of whether a patient
commenced treatment.
Demographic characteristics and stage of dementia were
similar across the three groups (table 1), but there was a slight
imbalance on severe impairment battery at baseline (10 point
difference in favour of patients in the placebo group).
Agitation inventory
There were no significant differences between treatments in the
change in agitation inventory scores between baseline and six
weeks and baseline and 26 weeks (table 2). Similar numbers
across the treatment groups showed an improvement in
agitation inventory score from baseline to six weeks (that is,
reduction in score) (fig 2).
Severe impairment battery
Fifty six of the 93 (60%) participants scored > 10 on the severe
impairment battery at baseline (20 rivastigmine, 17 quetiapine,
19 placebo). Forty six (82%) of these patients (14 rivastigmine, 14
quetiapine, 18 placebo) also completed it at six weeks. For these
46 patients, the mean (SD) scores at baseline were 71.6 (24.6)
placebo; 66.6 (21.3) quetiapine and 65.1 (22.6) rivastigmine (2.6,
7.2, and 6.3 points higher, respectively, than the scores at six
weeks). This could indicate that those with a poorer cognitive
function were more likely to drop out. Closer inspection of base-
line scores in those who did not complete a six week assessment,
however, showed that a combination of very high and very low
scores was evenly distributed throughout the three groups. In
contrast, baseline figures were almost identical for participants
who did or did not complete the agitation inventory at six weeks.
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Patients who received quetiapine experienced, on average, an
estimated mean difference in change in severe impairment bat-
tery score from baseline of − 14.6 points, compared with the pla-
cebo treated group at six weeks (95% confidence interval − 25.3
to − 4.0; P = 0.009); indicating a significantly greater deteriora-
tion in the quetiapine group (table 2 and fig 3). A similar magni-
tude of difference was evident at 26 weeks ( − 15.4, − 27.0 to
− 3.8, P = 0.01). In contrast, the corresponding comparison of
change in score from baseline for rivastigmine with placebo was
an average of − 3.5 points ( − 13.1 to 6.2) lower at six weeks
(P = 0.5) and − 7.5 points ( − 21.0 to 6.0) lower at 26 weeks
(P = 0.3).
Discussion
Compared with placebo, the atypical antipsychotic drug quetiap-
ine does not result in significant improvement in agitation in
patients with dementia and is associated with a greater decline in
cognitive function. This result is consistent with data from previ-
ous observational and preliminary clinical trials,7 highlighting a
doubling in the rate of cognitive decline in patients with demen-
tia taking antipsychotics. As we have shown this in a randomised
controlled trial, it is unlikely that the differences can be explained
by any potential confounding factors. These results have clear
implications for clinical practice.
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Allocated to rivastigmine (n=31)
Started allocated treatment (n=25, 81%)
Did not start allocated treatment (n=6, 19%)
 Withdrew consent (n=4)
 Died before treatment (n=2)
Allocated to quetiapine (n=31)
Started allocated treatment (n=26, 84%)
Did not start allocated treatment (n=5, 16%)
 Withdrew consent (n=4)
 Died before treatment (n=1)
Allocated to placebo (n=31)
Started allocated treatment (n=29, 94%)
Did not start allocated treatment (n=2, 6%)
 Withdrew consent (n=2)
Excluded (n=189, 67%)
 Consent not obtained (n=132)
 Ineligible (n=43)
 Died (n=14)
Lost to follow up (n=5)
 Behaviour deteriorated (n=2)
 Withdrew consent to treatment (n=3)
Lost to follow up (n=3)
 Died (n=1)
 Significant non-compliance (n=1)
 Other (n=1)
Lost to follow up (n=0)
Completed 6 week (n=21)
 On treatment (n=18)
 Not on treatment (n=3)
  Withdrew consent to treatment (n=1)
  Physical condition deteriorated (n=1)
  Protocol violation (n=1)
Completed 6 week (n=23)
 On treatment (n=21)
 Not on treatment (n=2)
  Withdrew consent to treatment (n=2)
Completed 6 week (n=30)
 On treatment (n=27)
 Not on treatment (n=3)
  Withdrew consent to treatment (n=2)
  Serious adverse event (n=1)
Fig 1 Flow of participants through trial
Table 1 Demographic and clinical characteristics and assessments at baseline
Baseline characteristics Rivastigmine (n=31) Quetiapine (n=31) Placebo (n=31) Overall (n=93)
Mean (SD) age (years) 84.3 (7.8) 84.2 (8.6) 83.0 (6.8) 83.8 (7.7)
No (%) of women 23 (74.2) 27 (87.1) 24 (77.4) 74 (79.6)
No (%) with significant EPS (M-UPDRS
≥8)
4 (12.9) 4 (12.9) 2 (6.5) 10 (10.8)
Mean (SD) SIB* (No of patients) 58.8 (27.2) (n=21) 59.4 (30.5) (n=20) 69.0 (28.2) (n=20) 62.3 (28.5) (n=61)
Mean (SD) CMAI† (No of patients) 61.1 (20.5) (n=28) 59.1 (16.2) (n=28) 56.4 (16.6) (n=31) 58.8 (17.7) (n=87)
Median (range) FAST (No of patients) 6 (4-7) (n=26) 6 (4-7) (n=28) 6 (4-7) (n=30) 6 (4-7) (n=84)
EPS=extrapyramidal symptoms; M-UPDRS=modified unified Parkinson’s disease rating scale; SIB=severe impairment battery; CMAI=Cohen-Mansfield agitation inventory; FAST=functional
assessment staging.
*Range 0-100. Higher scores mean better performance.
†Range 29-203. Higher scores mean more agitation. Scores >40 usually accepted as clinically significant.
Table 2 Summary of change from baseline at six weeks and 26 weeks for main outcomes plus comparative statistics
Rivastigmine Quetiapine Placebo
Mean difference (95% CI), P value
Rivastigmine v placebo Quetiapine v placebo Rivastigmine v quetiapine
Mean (SD) change in CMAI from baseline:
To week 6 −5.1 (16.3)
(n=24)
−4.0 (15.4)
(n=27)
−6.2 (17.6)
(n=29)
4.1 (−4.2 to 12.3), P=0.3 3.5 (−3.7 to 10.8), P=0.3 0.29 (−8.0 to 8.6), P=0.9
To week 26 −10.8 (19.9)
(n=24)
−8.1 (12.7)
(n=27)
−9.0 (16.5)
(n=30)
2.2 (−5.3 to 9.7), P=0.6 2.0 (−4.2 to 8.3); P=0.5 −0.52 (−8.0 to 6.9), P=0.9
Mean (SD) change in SIB from baseline:
To week 6 1.8 (14.7)
(n=14)
−10.5 (14.8)
(n=14)
3.2 (15.1)
(n=18)
−3.5 (−13.1 to 6.2), P=0.5 −14.6 (−25.3 to −4.0),
P=0.009
12.0 (0.76 to 23.2), P=0.04
To week 26 −3.1 (20.6)
(n=15)
−11.3 (15.6)
(n=15)
3.3 (17.4)
(n=19)
−7.5 (−21.0 to 6.0), P=0.3 −15.4 (−27.0 to −3.8), P=0.01 8.3 (−5.6 to 22.3), P=0.2
Papers
BMJ Online First bmj.com page 3 of 5
Even though quetiapine has a relatively more favourable
pharmacological profile than other antipsychotic agents, it was
still associated with a detrimental impact on cognition. One pos-
tulated mechanism is suppression of brain derived neurotrophic
factor (BDNF), accelerating the accumulation of the core patho-
logical substrates of Alzheimer’s disease.14 Another possible
mechanism involves antimuscarinic properties.15 Although
quetiapine has substantially less antimuscarinic activity than
some antipsychotics—such as olanzapine, clozapine, and
thioridazine—it does have 50% of the antimuscarinic activity of
chlorpromazine and more than twice that of risperidone.16 The
mechanism may be unrelated to any of these effects but
mediated through an impact on other trophic factors. Our find-
ings are contrary to preliminary reports that indicated potential
cognitive benefits of quetiapine in people with schizophrenia,17
although the mechanisms of cognitive impairment in the two
conditions are completely different.
Patients in the rivastigmine group did not experience any
significant improvement in agitation nor did they seem to expe-
rience a significant decline in cognitive function compared with
patients in the placebo group. Further larger studies are
indicated to determine the potential value of central cholineste-
rase inhibitors on cognition and behaviour in people with severe
dementia and clinically significant agitation.
Strengths and limitations
Patients in the placebo group had an average improvement of
6.2 points on their agitation inventory score and an average
improvement of 3.2 points on their severe impairment battery
over six weeks. This improvement is consistent with most previ-
ous reports.3 Trials focusing on cognition often report improve-
ments in placebo groups over three to four months, although
they do not usually persist for as long as 26 weeks. The modest
improvement we observed is probably explained by a
Hawthorne effect—namely, residents in an unstimulating
environment18 respond positively to the increased interaction as
part of the study procedures. Though our study is limited
because of the modest sample size, multiple evaluations, and the
substantial proportion of patients who were unable to complete
the severe impairment battery, the possible impact of quetiapine
on cognition is clinically important.
We did not adjust for multiple significance testing because we
considered the six week results would be the most important
because of the anticipated dropout rate; comparison of
treatment versus placebo was of primary importance, hence the
interpretation of the significant result; and comparison of active
treatments was always going to be of secondary importance,
hence the caution with the six week result for rivastigmine versus
quetiapine. When interpreting the cognitive function result for
quetiapine compared with placebo, it can be argued that, in the
light of a lack of evidence of efficacy, even a suggestion of a
decline in what was a secondary outcome is noteworthy. As one
could argue that it is not necessary to show significant evidence
of harm under these particular circumstances, a formal
adjustment was not deemed necessary.
The severe impairment battery has good concurrent validity
and is sensitive to longitudinal change19 in people with severe
dementia. In addition, it has been used in several placebo
controlled trials of central cholinesterase inhibitors20 or meman-
tine21 in people with severe dementia, showing enough sensitivity
to identify benefits of treatment. It is, therefore, a robust measure
of cognitive change in these patients.
Conclusion
Given current concerns about the risk of stroke with risperidone
and olanzapine,4 further studies are required to enable evidence
based pharmacological management of behavioural disturbance
in dementia. Quetiapine and rivastigmine seemed of no benefit
in patients with dementia and agitation in institutional care, and
quetiapine was associated with greater cognitive decline than
placebo. Our results suggest that quetiapine should not be used
as an alternative treatment to risperidone or olanzapine in peo-
ple with dementia and highlight concerns regarding the long
term use of antipsychotics in these patients.
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Fig 2 Change in score on Cohen-Mansfield agitation inventory (baseline to six
weeks) by treatment group
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What is already known on this topic
Antipsychotic drugs are widely used for the control of
behavioural manifestations in dementia, of which agitation
is the most common
Central cholinesterase inhibitors are increasingly used to
treat the behavioural manifestations of dementia
Observational data have suggested that (typical)
antipsychotics might accelerate cognitive decline in
dementia
What this study adds
Central cholinesterase inhibitors and atypical antipsychotics
are not effective for the treatment of agitation in people
with dementia
Quetiapine (an atypical antipsychotic) is associated with
accelerated cognitive decline
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